These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20600940)

  • 1. Human papillomavirus-like particles vaccine efficiently produced in a non-fermentative system based on insect larva.
    Millán AF; Gómez-Sebastián S; Nuñez MC; Veramendi J; Escribano JM
    Protein Expr Purif; 2010 Nov; 74(1):1-8. PubMed ID: 20600940
    [No Abstract]   [Full Text] [Related]  

  • 2. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.
    Bolhassani A; Shirbaghaee Z; Agi E; Davoudi N
    Protein Expr Purif; 2015 Dec; 116():7-11. PubMed ID: 26304732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
    Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
    Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity.
    Schädlich L; Senger T; Kirschning CJ; Müller M; Gissmann L
    Vaccine; 2009 Mar; 27(10):1511-22. PubMed ID: 19174177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
    Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
    Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
    Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic DNA immunization against multiple papillomavirus types.
    Gasparić M; Rubio I; Thönes N; Gissmann L; Müller M
    Vaccine; 2007 Jun; 25(23):4540-53. PubMed ID: 17485151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prokaryotic expression and purification of human papillomavirus type 11 L2E7 fusion protein vaccine and its immunnogenicity].
    Zhang H; Zhao L; Ren J; Gao J; Bian T; Fan JT; Ruan L; Chen XQ; Tian HW
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):156-8. PubMed ID: 17653322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of an HPV-16 L2 DNA vaccine.
    Hitzeroth II; Passmore JA; Shephard E; Stewart D; Müller M; Williamson AL; Rybicki EP; Kast WM
    Vaccine; 2009 Oct; 27(46):6432-4. PubMed ID: 19559114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The L1 protein of human papilloma virus 16 expressed by a fowlpox virus recombinant can assemble into virus-like particles in mammalian cell lines but elicits a non-neutralising humoral response.
    Bissa M; Zanotto C; Pacchioni S; Volonté L; Venuti A; Lembo D; De Giuli Morghen C; Radaelli A
    Antiviral Res; 2015 Apr; 116():67-75. PubMed ID: 25660110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
    Rubio I; Bolchi A; Moretto N; Canali E; Gissmann L; Tommasino M; Müller M; Ottonello S
    Vaccine; 2009 Mar; 27(13):1949-56. PubMed ID: 19368776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prokaryotic expression of HPV 16 L1 gene and identification of its immune activity].
    Hao DF; Ma ZH; Wang YP; Rexidan ; Zhang FC
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jul; 21(4):428-31. PubMed ID: 15989783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer.
    Gupta SK; Singh A; Srivastava M; Gupta SK; Akhoon BA
    Vaccine; 2009 Dec; 28(1):120-31. PubMed ID: 19799841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of human papillomavirus type 16 L1 in baculovirus expression systems: a case study.
    Jin Z; Lusheng S; Yili W
    Methods Mol Biol; 2005; 308():77-86. PubMed ID: 16082027
    [No Abstract]   [Full Text] [Related]  

  • 16. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity].
    Wei MX; Li SW; Huang B; Shen WT; Su YZ; Zhang CH; Gu Y; Du HL; Zhang J; Xia NS
    Bing Du Xue Bao; 2009 Jul; 25(4):245-50. PubMed ID: 19769155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo mechanisms of vaccine-induced protection against HPV infection.
    Day PM; Kines RC; Thompson CD; Jagu S; Roden RB; Lowy DR; Schiller JT
    Cell Host Microbe; 2010 Sep; 8(3):260-70. PubMed ID: 20833377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.
    Mejia AF; Culp TD; Cladel NM; Balogh KK; Budgeon LR; Buck CB; Christensen ND
    J Virol; 2006 Dec; 80(24):12393-7. PubMed ID: 17005666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies.
    Xie X; Liu Y; Zhang T; Xu Y; Bao Q; Chen X; Liu H; Xu X
    Arch Virol; 2013 Jan; 158(1):193-9. PubMed ID: 22965579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.